Adverum Biotechnologies, Inc. (ADVM) Reaches $7.15 After 8.00% Up Move; Shorts at Veritone (VERI) Lowered By 0.81%

March 14, 2018 - By Dolores Ford

Veritone Inc (NASDAQ:VERI) had a decrease of 0.81% in short interest. VERI’s SI was 1.22 million shares in March as released by FINRA. Its down 0.81% from 1.23M shares previously. With 357,100 avg volume, 3 days are for Veritone Inc (NASDAQ:VERI)’s short sellers to cover VERI’s short positions. The SI to Veritone Inc’s float is 19.45%. The stock increased 0.77% or $0.11 during the last trading session, reaching $14.47. About 52,170 shares traded. Veritone, Inc. (NASDAQ:VERI) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a huge mover today! The stock increased 2.88% or $0.2 during the last trading session, reaching $7.15. About 351,601 shares traded. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has declined 30.48% since March 14, 2017 and is downtrending. It has underperformed by 47.18% the S&P500.The move comes after 7 months positive chart setup for the $444.54M company. It was reported on Mar, 14 by We have $7.72 PT which if reached, will make NASDAQ:ADVM worth $35.56M more.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $444.54 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

Analysts await Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report earnings on May, 8. They expect $-0.29 earnings per share, up 23.68% or $0.09 from last year’s $-0.38 per share. After $-0.32 actual earnings per share reported by Adverum Biotechnologies, Inc. for the previous quarter, Wall Street now forecasts -9.38% EPS growth.

Veritone, Inc., a cloud-based cognitive software company, develops a proprietary artificial intelligence platform for various markets in the United States and internationally. The company has market cap of $233.82 million. The Company’s cloud open platform integrates and orchestrates an ecosystem of cognitive engines to reveal multivariate insights from various amounts of audio, video, and structured data; and incorporates proprietary technology to manage and integrate a range of AI processes to mimic human cognitive functions comprising perception, reasoning, prediction, and problem solving to transform unstructured data into structured data. It currently has negative earnings. The firm offers media agency services, including media planning and strategy, media buying and placement, campaign messaging, clearance verification and attribution, and custom analytics to manage, deliver, optimize, verify, and quantify advertising campaigns and content distribution for various clients across multiple channels comprising broadcast radio, satellite audio, streaming audio, broadcast and cable television, digital video, and podcasting.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: